Wharton's jelly stem cells
Wharton's jelly is the gelatinous connective tissue inside the umbilical cord. It is a rich source of young mesenchymal stem cells that can be collected non-invasively after a consented, healthy full-term birth and expanded in a GMP laboratory.
Why Wharton jelly stem cells are used
Compared with adult sources, Wharton's jelly MSCs are proliferative, consistent between batches and have low immunogenicity, which is what makes allogeneic (donor) use feasible. Collection carries no risk or discomfort for the donor because the cord is otherwise discarded.
- High expansion capacity — clinically useful doses from a single consented donation
- Low HLA class II expression — supports allogeneic use
- Strong immunomodulatory secretome
- No bone marrow aspiration or liposuction required from the patient
- Screened, documented donation with a release certificate — see credentials and quality
What are Wharton's jelly stem cells and why are they used?
Wharton's jelly is the connective tissue of the umbilical cord. The mesenchymal stem cells isolated from it are young, expand readily in culture and are collected after consented, non-invasive donation at birth. Compared with bone marrow harvesting, donation carries no risk to the patient and yields consistent cell numbers, which is why many GMP laboratories prefer this source.
Key facts
- Source
- Donated umbilical cord tissue, with consent
- Donor risk
- None — tissue is otherwise discarded
- Advantage
- High proliferation, consistent yield
- Screening
- Donor infectious-disease screening before use
What we know
- Wharton's jelly MSCs proliferate faster than adult bone-marrow MSCs in culture.
- Allogeneic use is standard because MSCs are low in HLA class II expression.
What remains uncertain
- Head-to-head clinical trials comparing cord-derived and bone-marrow MSCs are scarce.
Medically reviewed questions
This summary is general medical information, not medical advice, and not a promise of benefit. Figures are quoted ranges, confirmed in writing after a medical review.
Medically reviewed by: Prof. Dr. Erdal Karaöz · Last updated: · Editorial and evidence policy
Wharton's jelly vs bone marrow vs adipose MSCs
Bone marrow MSCs are well studied but require an invasive harvest and decline in yield with donor age. Adipose MSCs are abundant but also age with the patient. Wharton's jelly MSCs avoid both problems, at the cost of being allogeneic rather than autologous. The comparison is set out in cord blood versus bone marrow and why Wharton's jelly MSCs are considered.
How they are processed and released
Tissue is transported under controlled conditions, cells are isolated and expanded in a GMP-certified laboratory, and each batch is tested for identity, viability, sterility, mycoplasma and endotoxin before release. Patients can request the release documentation before travelling — how to read it is explained in our lab report guide.
Frequently asked questions
Are Wharton's jelly stem cells ethical?
Yes. The umbilical cord is collected with written consent after a healthy full-term delivery and would otherwise be discarded. No embryonic tissue is involved.
Will my body reject donor cord cells?
Wharton's jelly MSCs have low immunogenicity and are widely used allogeneically. Reactions are usually limited to transient infusion-related effects, and eligibility is checked beforehand.
How many cells are given?
Dose depends on indication, delivery route and body weight, and is specified in the individual plan rather than as a fixed package number.
Ask whether this is right for you
Share your diagnosis and recent records. Our medical team in Istanbul reviews candidacy, alternatives and realistic goals before any treatment plan is proposed.
Request a free medical review